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Abstract {#s1}
========

There have been significant advances in the treatment landscape of lung cancer in the recent few years. In this podcast, Jonathan Lim (a member of the European Society for Medical Oncology Young Oncologists Committee) interviews Professor Sanjay Popat (Professor of Thoracic Medical Oncology at The Royal Marsden Hospital, UK) on the highlights of lung cancer in 2019.

Professor Popat provides his perspective and contextualises how some of the key studies reported this year (including CheckMate 227, IMpower110, KEYNOTE 042, FLAURA and CASPIAN) have been practice-changing. We also discuss the current utility and caveats of PD-L1(programmed death-ligand 1) as a biomarker for immunotherapy with anti-PD1, and explore progress made in the clinical translation of circulating tumour DNA, circulating tumour cell and tumour mutational burden. Finally, we talk about the recent hype on targeting KRAS in non-small cell lung cancer, and highlight what is on the horizon in 2020.
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